Recombinant Probiotics for Inflamed Gut Colonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Probiotics face challenges in colonizing the gastrointestinal tract effectively, especially in inflamed regions, due to competition from native aerobic bacteria and sensitivity to reactive oxygen species, leading to low efficacy in reducing inflammation in inflammatory bowel disease.
Innovation Solution
Development of recombinant probiotic bacteria expressing N-acetyl-glucosamine binding protein A and tetrathionate reductase, which enhance colonization and persistence by binding to mucins and utilizing tetrathionate, respectively, to improve colonization and anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If probiotics are administered to colonize the gastrointestinal tract, then they aim to reduce inflammation, but they face strong competition from native aerobic bacteria and are sensitive to reactive oxygen species, resulting in low efficacy
Solution Approach 1:
The patent applies parameter changes by engineering probiotic bacteria with modified genetic parameters - specifically introducing the ttr operon for tetrathionate utilization and gbpA gene for mucin binding - to enhance their ability to survive and colonize in the inflamed gastrointestinal environment despite competition from native bacteria and ROS sensitivity
Solution Approach 2:
The patent creates composite biological systems by combining multiple functional elements within the probiotic bacteria: the ttr operon (ttrABC genes) for tetrathionate reductase activity, the gbpA gene for N-acetyl-glucosamine binding protein, and the native probiotic core, resulting in a composite strain with enhanced colonization and anti-inflammatory capabilities
2Duration of action of stationary object
If probiotics attempt to colonize the gut, then they may provide health benefits, but they are diluted out by existing microbiota unless replenished by fresh inoculum
Solution Approach 1:
The patent applies preliminary action by equipping probiotic bacteria with pre-acquired advantages before they encounter native microbiota - specifically, the ttr operon enables utilization of tetrathionate (an abundant electron acceptor in inflamed guts) and the gbpA gene provides preliminary mucin binding capability, allowing these probiotics to establish footholds before being diluted by existing microbiota
Solution Approach 2:
The patent implements self-service mechanisms where the probiotic bacteria utilize their own engineered metabolic pathways - the ttr operon enables them to self-generate energy from tetrathionate reduction, and the gbpA protein enables self-adhesion to mucins - allowing them to sustain colonization without external replenishment
3Reliability
If aerobic probiotic species with anti-inflammatory effects are used, then they may provide therapeutic benefits, but inflammation sites are already heavily colonized with native gut aerobes creating colonization resistance
Solution Approach 1:
The patent applies parameter changes by modifying the metabolic parameters of aerobic probiotics - introducing the ttr operon enables them to utilize tetrathionate as an electron acceptor, providing a metabolic advantage in inflamed environments where tetrathionate is abundant, thereby overcoming colonization resistance from native aerobes while maintaining anti-inflammatory effects
Solution Approach 2:
The patent applies local quality by providing the probiotic bacteria with site-specific adaptations - the gbpA gene confers localized mucin binding capability specifically useful at the mucosal interface of inflamed tissues, while the ttr operon provides localized metabolic advantage in the anaerobic/ microaerophilic conditions of inflamed gut regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant probiotic bacteria demonstrate improved colonization and persistence in the gastrointestinal tract, effectively reducing inflammation and showing potential in treating inflammatory bowel disease.
Implementation Method 1
expressing an N-acetyl-glucosamine binding protein A or fragment or homologue thereof... binding to mucins
Implementation Method 2
tetrathionate reductase... promotes the growth of Salmonella in the intestinal lumen during inflammation... capacity to utilize tetrathionate
Data Source
AI summary
The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.